Y Intercept Hong Kong Ltd Acquires New Holdings in Prestige Consumer Healthcare Inc. $PBH

Y Intercept Hong Kong Ltd bought a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 3,266 shares of the company’s stock, valued at approximately $261,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Intech Investment Management LLC boosted its holdings in shares of Prestige Consumer Healthcare by 18.9% in the first quarter. Intech Investment Management LLC now owns 27,307 shares of the company’s stock valued at $2,348,000 after buying an additional 4,343 shares during the period. Voya Investment Management LLC lifted its position in Prestige Consumer Healthcare by 19.5% in the 1st quarter. Voya Investment Management LLC now owns 41,717 shares of the company’s stock valued at $3,586,000 after acquiring an additional 6,798 shares in the last quarter. XTX Topco Ltd boosted its stake in Prestige Consumer Healthcare by 354.0% in the 1st quarter. XTX Topco Ltd now owns 22,778 shares of the company’s stock worth $1,958,000 after purchasing an additional 17,761 shares during the period. Keystone Wealth Services LLC acquired a new position in Prestige Consumer Healthcare in the 2nd quarter worth $315,000. Finally, Envestnet Asset Management Inc. increased its holdings in Prestige Consumer Healthcare by 6.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 180,802 shares of the company’s stock worth $15,544,000 after purchasing an additional 10,876 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on PBH shares. Wall Street Zen lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Thursday, September 4th. Jefferies Financial Group cut their price objective on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a research report on Monday, October 27th. Finally, Oppenheimer reduced their target price on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a report on Tuesday, October 21st. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Hold” and an average price target of $85.33.

Prestige Consumer Healthcare Trading Down 2.5%

NYSE PBH opened at $59.85 on Friday. Prestige Consumer Healthcare Inc. has a 12 month low of $59.51 and a 12 month high of $90.04. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55. The stock has a 50 day moving average of $62.98 and a 200-day moving average of $73.18. The company has a market cap of $2.95 billion, a PE ratio of 14.05, a PEG ratio of 1.93 and a beta of 0.41.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm had revenue of $274.11 million during the quarter, compared to analysts’ expectations of $257.14 million. During the same quarter last year, the company posted $1.09 earnings per share. The company’s revenue for the quarter was down 3.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.